These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. BET inhibitors in cancer therapeutics: a patent review. Ghoshal A; Yugandhar D; Srivastava AK Expert Opin Ther Pat; 2016; 26(4):505-22. PubMed ID: 26924192 [TBL] [Abstract][Full Text] [Related]
3. QSAR and 3D-QSAR studies applied to compounds with anticonvulsant activity. Garro Martinez JC; Vega-Hissi EG; Andrada MF; Estrada MR Expert Opin Drug Discov; 2015 Jan; 10(1):37-51. PubMed ID: 25297377 [TBL] [Abstract][Full Text] [Related]
4. Novel pharmacological modulators of autophagy: an updated patent review (2012-2015). Ha J; Kim J Expert Opin Ther Pat; 2016 Nov; 26(11):1273-1289. PubMed ID: 27476990 [TBL] [Abstract][Full Text] [Related]
5. Recent progress on curcumin-based therapeutics: a patent review (2012-2016). Part II: curcumin derivatives in cancer and neurodegeneration. Di Martino RMC; Bisi A; Rampa A; Gobbi S; Belluti F Expert Opin Ther Pat; 2017 Aug; 27(8):953-965. PubMed ID: 28597702 [TBL] [Abstract][Full Text] [Related]
6. Current state on tryptophan 2,3-dioxygenase inhibitors: a patent review. Kozlova A; Frédérick R Expert Opin Ther Pat; 2019 Jan; 29(1):11-23. PubMed ID: 30526149 [TBL] [Abstract][Full Text] [Related]
7. Quantitative structure-activity relationship: promising advances in drug discovery platforms. Wang T; Wu MB; Lin JP; Yang LR Expert Opin Drug Discov; 2015 Dec; 10(12):1283-300. PubMed ID: 26358617 [TBL] [Abstract][Full Text] [Related]
8. QSAR studies in the discovery of novel type-II diabetic therapies. Abuhammad A; Taha MO Expert Opin Drug Discov; 2016; 11(2):197-214. PubMed ID: 26558613 [TBL] [Abstract][Full Text] [Related]
9. Recent development on naphthoquinone derivatives and their therapeutic applications as anticancer agents. Tandon VK; Kumar S Expert Opin Ther Pat; 2013 Sep; 23(9):1087-108. PubMed ID: 23651032 [TBL] [Abstract][Full Text] [Related]
10. The advancement of multidimensional QSAR for novel drug discovery - where are we headed? Wang T; Yuan XS; Wu MB; Lin JP; Yang LR Expert Opin Drug Discov; 2017 Aug; 12(8):769-784. PubMed ID: 28562095 [TBL] [Abstract][Full Text] [Related]
11. In Silico Studies in Drug Research Against Neurodegenerative Diseases. Makhouri FR; Ghasemi JB Curr Neuropharmacol; 2018; 16(6):664-725. PubMed ID: 28831921 [TBL] [Abstract][Full Text] [Related]
12. Advances in quantitative structure-activity relationship models of anti-Alzheimer's agents. Ambure P; Roy K Expert Opin Drug Discov; 2014 Jun; 9(6):697-723. PubMed ID: 24754675 [TBL] [Abstract][Full Text] [Related]
13. Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2). Kim T; Pae AN Expert Opin Ther Pat; 2016 Nov; 26(11):1353-1366. PubMed ID: 27599163 [TBL] [Abstract][Full Text] [Related]
14. Ligands for Ser/Thr phosphoprotein phosphatases: a patent review (2005-2015). Lajarín-Cuesta R; Arribas RL; De Los Ríos C Expert Opin Ther Pat; 2016; 26(3):389-407. PubMed ID: 26853448 [TBL] [Abstract][Full Text] [Related]